At the news
? NEUTRALIMPACT 1/10 COURT-RULING filed Nov 12, 2026 at 19:00 ET
The court entered a stipulated protective order in Novo Nordisk's patent litigation against Mochi Health Corp., governing the handling of confidential information and trade secrets during discovery. This is a routine procedural step that does not resolve any substantive claims or impose any liability.
- Novo Nordisk A/S and Novo Nordisk Inc. are plaintiffs in a patent infringement case against Mochi Health Corp., Mochi Medical CA P.C., and Mochi Medical P.A.
- The case is pending in the Northern District of California, Case No. 5:25-cv-06563-EKL.
- The court entered a stipulated protective order on November 13, 2026, governing the designation and handling of confidential and highly confidential information.
- The protective order includes a prosecution bar restricting involvement in patent prosecution related to semaglutide or its analogs for one year after judgment or settlement.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access